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Effect of carnosine 
supplementation on the plasma 
lipidome in overweight and 
obese adults: a pilot randomised 
controlled trial
Estifanos Baye1, Jozef Ukropec2, Maximilian PJ de Courten  3, Silvia Vallova4, Patrik 
Krumpolec2, Timea Kurdiova2, Giancarlo Aldini5, Barbara Ukropcova2,4 & Barbora de Courten1
Carnosine has been shown to reduce oxidation and glycation of low density lipoprotein hence improving 
dyslipidaemia in rodents. The effect of carnosine on human plasma lipidome has thus far not been 
investigated. We aimed to determine whether carnosine supplementation improves the plasma 
lipidome in overweight and obese individuals. Lipid analysis was performed by liquid chromatography 
mass spectrometry in 24 overweight and obese adults: 13 were randomly assigned to 2 g carnosine 
daily and 11 to placebo, and treated for 12 weeks. Carnosine supplementation maintained 
trihexosylceramide (0.01 ± 0.19 vs −0.28 ± 0.34 nmol/ml, p = 0.04), phosphatidylcholine (77 ± 167 
vs −81 ± 196 nmol/ml, p = 0.01) and free cholesterol (20 ± 80 vs −69 ± 80 nmol/ml, p = 0.006) 
levels compared to placebo. Trihexosylceramide was inversely related with fasting insulin (r = −0.6, 
p = 0.002), insulin resistance (r = −0.6, p = 0.003), insulin secretion (r = −0.4, p = 0.05) and serum 
carnosinase 1 activity (r = −0.3, p = 0.05). Both phosphatidylcholine and free cholesterol did not 
correlate with any cardiometabolic parameters. Our data suggest that carnosine may have beneficial 
effects on the plasma lipidome. Future larger clinical trials are needed to confirm this.
Dyslipidaemia is one of the modifiable cardiometabolic risk factors that has been shown to play a significant 
role in the development of insulin resistance, type 2 diabetes (T2DM) and cardiovascular diseases (CVD)1–3. In 
clinical practice, dyslipidaemia is usually defined as increased total cholesterol and low density lipoprotein (LDL) 
with decreased high density lipoprotein (HDL) levels3. This provides a very narrow snapshot of the dynamic pro-
cesses involved in lipid metabolism4. In addition, these traditional clinical measures are not sufficient to explain 
the complexity of lipid metabolism which are known to be altered in obese individuals, patients with meta-
bolic syndrome and T2DM, and individuals with high cardiovascular risk5–7. Lipidomics approach can provide 
new insight into the lipid metabolism by offering a chance to examine the lipid classes and species in plasma4,5. 
Lipidomics is focused on the comprehensive identification and quantification of all lipids from serum, plasma, 
tissue, whole organism or cell8. Lipid profiling has shown promising results in the identification of metabolic bio-
markers, understanding the mechanisms of lipid metabolism, and diagnosis of various conditions and diseases 
such as obesity, metabolic syndrome, T2DM and CVD as well as in determining responses to therapeutic inter-
ventions9–12. Recently, plasma lipid classes and species have been shown to associate with T2DM and CVD5,13–15.
Carnosine is an over-the-counter food supplement and it has been shown to prevent and treat several chronic 
diseases16 through its anti-inflammatory, antioxidant, anti-glycation, anti-ischaemic and chelating properties17–19. 
We have previously demonstrated that carnosine supplementation prevented worsening of insulin resistance in 
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non-diabetic overweight and obese individuals, but did not change plasma lipid profiles such as total and HDL 
cholesterols, and triglycerides20. However, in both diabetic and non-diabetic rodents, carnosine has been shown 
to improve dyslipidaemia, reduce oxidation and glycation of LDL and reduce development of atherosclerosis21,22. 
We have therefore hypothesised that carnosine supplementation may have beneficial effect on the plasma lipi-
dome in overweight and obese individuals which will be related to cardiometabolic parameters.
Results
Baseline characteristics. Twenty-four participants (13 in carnosine, 11 placebo group) were included in 
this analysis. Of these, six of them were females (3 in each group). The overall mean age of the participants’ were 
43 ± 7 years with a body mass index of 31 ± 4.5 kg/m2. Baseline anthropometric and blood pressure measure-
ments, glucose parameters, lipid profiles, inflammatory markers, urinary carnosine levels, and serum carnosinase 
activity and content were not different between the groups (Table 1). Dietary fat preference and resting energy 
expenditure did not differ between the groups. Similarly, levels of lipid classes at baseline were not different in 
carnosine and placebo groups (Table 2).
Effect of carnosine supplementation on the plasma lipidome. Carnosine supplementation main-
tained the levels of trihexosylceramide (THC) (mean change from baseline ± standard deviation: 0.01 ± 0.19 
versus −0.28 ± 0.34 nmol/ml, p = 0.04) and phosphatidylcholine (PC) (77 ± 167 versus −81 ± 196 nmol/ml, 
p = 0.01) lipid classes compared to placebo. Free cholesterol (COH) was also preserved in the carnosine 
group than placebo (20 ± 80 versus −69 ± 80 nmol/ml, p = 0.006). None of the other lipid classes showed 
changes between the groups (Table 2).
Relationship between lipid classes and cardiometabolic parameters. Change in THC was 
inversely related with change in fasting insulin levels (r = −0.6, p = 0.002), HOMA-IR (r = −0.6, p = 0.003), 
HOMA-B (r = −0.4, p = 0.05) and serum carnosinase 1 activity (r = −0.5, p = 0.01). These associations except for 
HOMA-B were significant after adjustment for age, sex, and change in BMI (all p < 0.03). THC did not correlate 
with other cardiometabolic parameters and carnosine measurements (all p > 0.2). PC was positively correlated 
with BMI (r = 0.4, p = 0.04), however this relationship was not significant after adjusting either for age or sex 
(all p > 0.05). Both PC and COH did not associate with anthropometric measures, metabolic or cardiovascular 
parameters, and urinary carnosine levels as well as serum carnosinase 1 activity/content (all p > 0.1). THC, PC 





(n = 11) P-value
Sex F = 3, M = 10 F = 3, M = 8
Age (years) 42 ± 6 43 ± 9 0.73
Body mass index (kg/m2) 30.4 ± 4.5 32.3 ± 4.6 0.32
Waist-to-hip ratio 0.89 ± 0.06 0.88 ± 0.06 0.74
Systolic BP (mm Hg) 117.1 ± 8.8 125.1 ± 13.3 0.09
Diastolic BP (mm Hg) 76.1 ± 5.5 83.1 ± 9.2 0.06
Fasting glucose (mmol/l) 5.4 ± 0.46 5.3 ± 0.50 0.60
2 h glucose (mmol/l) 6.6 ± 2.0 7.5 ± 2.4 0.35
Fasting insulin (mU/l) 12.4 ± 7.3 14.3 ± 5.4 0.49
2 h insulin (mU/l) 109.5 ± 75.9 127.5 ± 84.6 0.58
HOMA-IR 3.0 ± 2.0 3.2 ± 1.2 0.69
HOMA-B 136.3 ± 55.1 182.1 ± 89.9 0.14
Total cholesterol (mmol/l) 5.4 ± 0.9 5.3 ± 0.8 0.77
High density lipoprotein (mmol/l) 1.2 ± 0.3 1.2 ± 0.2 0.97
Triglycerides (mmol/l) 1.8 ± 1.0 1.5 ± 0.5 0.41
C-reactive protein (mg/l) 3.4 ± 2.9 4.4 ± 4.6 0.50
Adiponectin (µmol/ml) 5.9 ± 3.3 5.8 ± 1.8 0.96
Urinary carnosine levels (nmol/ml) 8.9 ± 6.1 8.0 ± 6.3 0.73
Carnosinase 1 activity (µM) 1.8 ± 0.8 2.1 ± 0.6 0.39
Fat preference score (high fat/low fat score) 0.94 ± 0.13 0.86 ± 0.12 0.12
REE (kcal/kg/day) 32.3 ± 4.6 32.3 ± 6.5 0.99
Table 1. Participant baseline characteristics. Means and standard deviations were reported. Independent t-tests 
were computed to determine the p-value. BP, blood pressure; HOMA-B, homeostatic model of assessment 
of insulin secretion; HOMA-IR, homeostatic model of assessment of insulin resistance; REE, resting energy 
expenditure.
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Discussion
We measured the effect of carnosine supplementation on the plasma lipidome in non-diabetic overweight and 
obese adults from a randomised double-blind placebo controlled pilot trial. We have demonstrated that supple-
mentation with 2 g carnosine daily for 12 weeks resulted in changes in plasma lipidome which were associated 
with improved insulin sensitivity and secretion as well as serum carnosinase 1 activity.
We have demonestrated that THC levels were maintained after carnosine supplementation compared to pla-
cebo, which showed a relative increase in the carnosine group. This finding is consistent with the recent data that 
showed higher levels of THC after lifestyle intervention (diet and exercise) in patients with metabolic syndrome 
compared to dietary intervention only and no intervention23. Treatment with RVX-208, first-in-class BET inhib-
itor with apolipoprotein A-I inducing effects, has also been shown to increase THC levels in prediabetes males 
compared to placebo24. THC constitutes the main components of cell membranes and has been suggested to have 
beneficial roles in signal transmission, cell adhesion, growth factor regulation and protein transport25. These 
mechanisms have been shown to play a role in the development of insulin resistance and T2DM26. Meikle and 
colleagues have reported that THC was inversely associated with obesity27, plasma glucose level and decreased 
with prediabetes and T2DM14. Lower levels of THC was also observed in people with metabolic syndrome23. 
Similarly, we have found that THC was inversely associated with fasting insulin, insulin resistance, and insulin 
secretion. We showed, however, no association with other glycaemic measures (fasting glucose, 2 h glucose and 
insulin levels), anthropometric measures and inflammatory markers. This is likely because our study population 
was overweight and obese but did not have with other features of metabolic syndrome. Importantly, THC was 
inversely associated with serum carnosinase 1 activity. Low serum carnosinase 1 activity increases circulating 
carnosine in humans28. We did not, however, find any association between THC and urinary carnosine levels. 
Nonetheless, we have previously shown that supplementation with carnosine increased the level of carnosine in 
urine and prevented worsening of insulin sensitivity in non-diabetic overweight and obese adults20. Therefore, 
the observed effect of carnosine on THC levels may suggest its promising effect in normalising the plasma lipid 
profile in high risk groups which may have a role in preventing the development of insulin resistance and T2DM.
Lipid class
Carnosine group (n = 13) Placebo group (n = 11)
P* P#Baseline Change from baseline Baseline Change from baseline
dhCer 0.93 ± 0.22 0.19 ± 0.24 0.99 ± 0.31 0.02 ± 0.27 0.53 0.15
Cer 7.26 ± 1.47 0.06 ± 1.03 6.65 ± 1.24 −0.22 ± 0.63 0.28 0.08
MHC 19.22 ± 4.34 −0.78 ± 3.54 16.28 ± 3.57 −0.86 ± 1.09 0.08 0.16
DHC 9.29 ± 1.82 −0.66 ± 1.13 8.60 ± 1.53 −0.95 ± 1.45 0.33 0.21
THC 1.78 ± 0.43 0.01 ± 0.19 1.98 ± 0.45 −0.28 ± 0.34 0.26 0.04
GM3 5.34 ± 1.27 −0.09 ± 0.55 4.99 ± 1.04 −0.38 ± 0.56 0.48 0.20
SM 421.38 ± 73.29 −9.74 ± 36.72 425.35 ± 98.92 −31.23 ± 54.22 0.91 0.10
PC 1821.96 ± 264.12 77.28 ± 16.70 1801.78 ± 282.53 −81.27 ± 196.02 0.85 0.01
PC(O) 82.05 ± 12.17 1.27 ± 14.86 90.43 ± 15.54 −3.59 ± 11.64 0.15 0.84
PC(P) 41.35 ± 5.98 0.49 ± 5.81 45.35 ± 11.45 −2.26 ± 8.07 0.28 0.67
LPC 118.67 ± 14.52 −5.15 ± 19.41 105.99 ± 24.54 −10.20 ± 14.21 0.13 0.14
LPC(O) 1.71 ± 0.11 −0.14 ± 0.25 1.69 ± 0.20 −0.01 ± 0.13 0.85 0.68
PE 32.63 ± 9.51 −0.046 ± 5.91 31.51 ± 11.16 −0.10 ± 7.29 0.79 0.81
PE(O) 2.69 ± 1.00 0.14 ± 1.13 2.92 ± 1.00 −0.08 ± 0.97 0.59 0.82
PE(P) 29.20 ± 5.41 2.79 ± 8.09 31.66 ± 5.41 0.19 ± 7.33 0.27 0.76
LPE 7.18 ± 1.47 −0.16 ± 1.73 6.41 ± 1.26 −0.35 ± 0.97 0.18 0.17
PI 44.22 ± 12.45 −1.71 ± 6.40 39.95 ± 8.58 −2.06 ± 6.43 0.34 0.27
LPI 0.74 ± 0.17 0.098 ± 0.19 0.73 ± 0.17 0.06 ± 0.13 0.88 0.49
PS 9.07 ± 3.09 0.05 ± 2.56 10.39 ± 4.53 −1.77 ± 5.89 0.40 0.55
PG 0.22 ± 0.13 −0.01 ± 0.07 0.18 ± 0.008 −0.01 ± 0.07 0.39 0.49
CE 1345.49 ± 251.06 5.49 ± 21.05 1254.97 ± 206.26 −22.47 ± 174.38 0.35 0.58
COH 896.96 ± 131.96 20.05 ± 79.62 933.82 ± 166.13 −68.56 ± 79.71 0.55 0.006
DG 40.86 ± 24.67 1.03 ± 15.39 35.88 ± 16.95 −0.04 ± 20.03 0.57 0.78
TG 347.22 ± 175.29 19.40 ± 129.72 289.03 ± 93.68 −4.31 ± 9.13 0.33 0.58
Table 2. Effect of carnosine supplementation on the plasma lipidome. All values are in nmol/ml. Means and 
standard deviations were reported. *Independent t-tests were conducted to compare the baseline differences 
between the groups. #Analysis of covariance were performed to determine between-group treatment 
differences. dhCer, dihydroceramide; Cer, ceramide; MHC, monohexosylceramide; DHC, dihexosylceramide; 
THC, trihexosylcermide; GM3, GM3 ganglioside; SM, sphingomyelin; PC, phosphatidylcholine; PC(O), 
alkylphosphatidylcholine; PC(P), alkenylphosphatidylcholine; PC, lysophosphatidylcholine; LPC(O), 
lysoalkylphosphatidylcholine; PE, phosphatidylethanolamine; PE(O), alkylphosphatidylethanolamine; 
PE(P), alkenylphosphatidylethanolamine; LPE, lysophosphatidylethanolamine; PI, phosphatidylinositol; LPI, 
lysophosphatidylinositol; PS, phosphatidylserine; PG, phosphatidylglycerol; CE, cholesterol ester; COH, free 
cholesterol; DG, diacylglycerol; TG, triacylglycerol.
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We report that supplementation with carnosine, as compared to placebo, improved plasma PC levels in over-
weight and obese, otherwise healthy individuals. In line with this, a study that involved older patients with estab-
lished CVD showed an increased plasma PC levels after treatment with rosuvastatin29. A single session of acute 
exercise has also tended to increase muscle PC levels in patients with T2DM30. PC is a major constituent of the 
plasma membrane and a key element of very-low-density lipoproteins. It serves as a precursor of signalling mol-
ecules31 and plays a role in exporting triglycerides to the organs32. A deficiency of PC in the secretory pathway 
or in the nascent particle may limit the secretion of very-low-density lipoproteins and leads to the accumulation 
of hepatic triglycerides32. Low cellular PC levels have been shown to activate sterol regulatory element-binding 
protein-1 (SREBP1), a transcription factor involved in glucose metabolism, thereby contribute to the develop-
ment of obesity, insulin resistance and fatty liver disease33. In support of this, previous reports demonstrated that 
PC was inversely related with insulin resistance30,34, T2DM35 and hepatic steatosis31. In our study, PC was not 
related with any cardiometabolic parameters. This could be due to the small sample size of the study or that our 
participants were all non-diabetic. Most importantly, carnosine supplementation has been shown to diminish the 
activity of SREBPs, reduce hepatic triglycerides, and improve insulin sensitivity in mice19. The beneficial effect of 
carnosine on PC levels may therefore contribute to the prevention of T2DM and CVD via regulation of SREBP-1 
activity.
We find that carnosine supplementation preserved plasma COH levels compared to placebo. A study in people 
with dyslipidaemia however showed a reduction in COH levels after treatment with simvastatin, as compared 
to placebo36. Another study also reported lower COH levels in patients with T2DM on statins than in those 
who were not37. Whilst these studies demonstrate the efficacy of statins in reducing COH levels in individuals 
with pre-existing altered lipid metabolism, supplementation with carnosine preserved COH levels in obese and 
overweight people with normal lipid profiles. Related to this, both high and low levels of COH have been shown 
to increase the risk of T2DM and CVD38–40. COH also has both anti- and pro-inflammatory roles41,42. These 
indicate that COH has U shape relationship with risk of T2DM and CVD40. COH is an essential component of 
cell membranes and is present in tissues or plasma lipoprotein. COH levels appear to be a physiological con-
stant that may be of considerable value in cholesterol metabolism43. Alterations in cholesterol metabolism could 
influence COH accumulation40. Obesity, insulin resistance and T2DM are associated with changes in cholesterol 
metabolism44. Elevated COH was observed in obesity34 and prediabetes14. In addition, COH was positively cor-
related with total and LDL-cholesterols in overweight and obese children45. Although we did not find any asso-
ciation between COH levels and cardiometabolic parameters, which could be due to that our participants were 
all healthy, the observed role of carnosine on COH levels may help to delay the development of T2DM and CVD 
through improving cholesterol metabolism. Our findings, however, should be confirmed in larger sample sizes.
Strengths and Limitations of the study. The study participants underwent a comprehensive metabolic 
profiling and were not different at baseline between the groups. Rigorous randomisation process was conducted 
in addition to blinding of the investigators, study personnel and study participants. We have analysed 24 lipid 
classes from 324 lipid species. Small sample size of the study could be considered as the main limitations of the 
study. Due to this, p-values for treatment difference between groups were not corrected for multiple comparisons, 
and the effect of carnosine on each lipid species were not analysed. Further studies using larger sample sizes are 
needed to confirm these preliminary findings, and determine the effect of carnosine supplementation on plasma 
lipid species as well.
Conclusions and Implications for clinical practice. In this exploratory analysis, we have demonstrated 
for the first time an effect of supplementation with carnosine on THC, PC and COH levels which are likely to have 
biological roles in the development of insulin resistance, T2DM and CVD. Although lifestyle interventions are 
effective strategies for prevention and treatment of T2DM and CVD, they are costly and difficult to implement at 
the population level. Carnosine, a safe and cheap over-the-counter food supplement, may therefore be an effective 
strategy to prevent or delay the development of insulin resistance and T2DM through improving the plasma lipid 
profile & metabolism. Future studies in larger sample sizes however are required to confirm these findings as well 
as to determine the putative effect of carnosine on each plasma lipid species.
Methods and Materials
Study design and population. Details of the trial protocol as well as primary outcomes have been 
published previously20. In brief, a randomised, double-blind, placebo-controlled trial was conducted in 30 
healthy overweight and obese individuals at the Institue of Experimental Endocrinology, Slovak Academy of 
Sciences, Slovakia. Eligible participants underwent a rigorous medical screening and they were asked to refrain 
from strenuous exercise and caffeine for 3 days prior to metabolic testing. All participants were non-diabetic 
as indicated by a 75 g oral glucose tolerance test (OGTT), non-smokers, and healthy according to a physical 
examination and routine blood analyses. Participants were randomly assigned either to receive 2 g  carnosine or 
identical placebo (2 g sucrose) daily (administered orally in two equivalent doses) for 12 weeks. No participant 
had signs of infection or took any medication or food supplements at the time of the study. Blood and urine col-
lections were performed after a 12 h overnight fast and 12 h after carnosine ingestion. Participants were asked to 
refrain from substantial lifestyle changes during the course of the study. As such, participants with weight change 
≥5 kg in the study period would be excluded from the study. We have excluded 3 participants (1 carnosine, 2 in 
placebo) for non-compliance with the protocol and 3 (2 carnosine, 1 placebo) participants had missing plasma 
samples.
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All volunteers were recruited from the community and written informed consent was taken prior to study 
entry. The protocol was approved by the Ethics Committee of the University Hospital Bratislava, Comenius 
University, Bratislava, Slovakia, and it conforms to the Ethical Declaration of Helsinki.
Anthropometric and blood pressure measurements. Body weight and height were measured and 
used to calculate body mass index (BMI). Blood pressure was measured in a sitting position after 30 minutes of 
rest using a Dinamap Compact (Johnson & Johnson Inc., UK). It was recorded three times, separated by 5 min-
utes, and the mean value was reported.
Assessment of dietary preference and resting energy expenditure. Food preference question-
naire was used to determine the participants’ dietary preference for high-fat/low-fat foods based on 72 differ-
ent food items. Resting energy expenditure (REE) was measured after an overnight fast by indirect calorimetry 
(Geratherm, Germany).
Metabolic studies. OGTTs were performed after a 12 h overnight fast and blood samples were collected in 
every 30 minutes for two hours to determine glucose tolerance status (American Diabetes Association criteria, 
2006). Serum glucose was analysed using glucosehexokinase 3 kit (Siemens Health Care Diagnostics, Germany) 
and insulin was determined with immunoradiometric assays (Immunotech, France). Insulin sensitivity and insu-
lin secretion was calculated using homeostatic model assessment of insulin resistance (HOMA-IR) and insulin 
secretion (HOMA-B) respectively. Total cholesterol, HDL, and triglycerides were measured using diagnostic kits 
from Roche (Germany). Hypersensitive C - reactive protein (hsCRP) and adiponectin were analysed by an immu-
noturbidimetric method (Randox, UK).
Measurement of carnosine levels and carnosinase activity. Urinary carnosine was measured using 
an internal standard and a triple quadrupole (TSQ QUANTUM ULTRA, Thermo Scientific, Italy), as previously 
described20,46. Serum carnosinase activity was quantified by fluorometric determination of liberated histidine 
after carnosine addition, and carnosinase content in serum was determined by a sandwich enzyme-linked immu-
nosorbent assay (ELISA) developed by Adelmann47, and as previously described20,48.
Lipidomic analysis. Lipid analysis was performed by liquid chromatography electrospray ionisation-tandem 
mass spectrometry using an Agilent 1200 liquid chromatography system combined with an Applied Biosystems 
API 4000 Q/TRAP mass spectrometer with a turboionspray source (350 °C) and Analyst 1.5 data system at Baker 
IDI Heart and Diabetes Institute, Australia. The detailed methods of analysis has been previously described else-
where27. Briefly, plasma samples (10 mL) were randomised (maintaining paired samples at baseline and after 
intervention), then extracted in a single-phase extraction with 20 volumes of CHCl3:MeOH (2:1) and 10 mL 
of an internal standard mix that contained between 50 and 1000 pmol each of 24 non physiologic and stable 
isotope-labelled lipid standards. The concentration of each lipid species was calculated by relating the peak area 
of each individual lipid species to the peak area of the corresponding internal standard. The integration of lipid 
chromatographic peaks was carried out by MassHunter Workstation Software (Agilent Technologies, USA). The 
concentration of individual lipids was calculated by relating the peak area of each lipid species to the peak area 
of the corresponding internal standard. A total of 324 lipid species in 24 lipid classes were analysed by multiple 
reaction monitoring experiments. The totals for each lipid class were calculated by adding the concentrations 
of individual lipid species within the same class27. Whole plasma was analysed in triplicate and the mean values 
of each triplicate subsequently used for statistical analysis. Assay performance was monitored by calculating 
the coefficient of variation (percent) of the quality control plasma samples across the entire analytical run. The 
median coefficient of variation of the internal standard areas and plasma quality control samples were 10% and 
7%, respectively, which indicate that the measurement had good precision (≤15%).
Statistical analysis. The sample size calculation was computed based on the primary outcome, insulin sen-
sitivity, and has been reported elsewhere20. Data analyses were performed using Stata V.14 (StatCorp LP, USA). 
Means and standard deviations were reported, unless otherwise stated. Appropriate data transformations were 
performed when needed. Independent student t-tests were conducted to compare the baseline participant char-
acteristics between carnosine and placebo groups. Treatment differences between the groups (between-group 
differences) were compared using analysis of covariance with the use of baseline values as covariates. Pearson 
correlations were used to determine the relationship between the lipid classes and cardiometabolic parameters. 
Linear regressions were performed to confirm the presence of the associations between lipid classes and cardio-
metabolic parameters after taking into account age, sex and BMI differences.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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